About this trial
Cardiac arrest is one of the critical illnesses that is directly life-threatening, and patients who survive cardiac arrest develop severe neurological deficits or even die. The effectiveness of drugs to improve neurological function in resuscitated brain-injured patients has been a focus of research in the field of resuscitation. Butanephthalein has an ameliorating effect on the damage of central nervous function in patients with acute ischemic stroke, and can promote the improvement of patients' neurological deficits. On this basis, the present study was designed as a multicenter, prospective randomized controlled experiment, with internationally accepted methods for assessing near-term and long-term neurological function, to determine the effectiveness of butalbital in improving neurological function after cardiac arrest, with the aim of searching for new methods and ideas to improve neurological function and prognosis after cardiac arrest.
Eligibility criteria
Qualifiers
Age 18-80 years old.
Glasgow Coma Scale (GCS) scores ≤8 upon admission.
Return of Spontaneous Circulation (ROSC) ≥30min.
Signed the informed consent form.
Disqualifiers
Cardiac arrest due to irreversible causes such as trauma, poisoning, etc.
Cardiac arrest due to end-stage conditions such as advanced cancer.
Persistent cardiogenic shock that is unreversed (defined as a systolic blood pressure persistently <90mmHg despite treatment with fluid resuscitation, vasopressor agents, and inotropic medications).
Presence of pre-existing cerebrovascular disease prior to cardiac arrest or confirmed intracranial hemorrhage by CT scan following admission.
Trial design
Treatments tested in this trial
- Butylphthalide and Sodium Chloride Injection
- Saline Solution
Treatment groups
Sponsors and collaborators
Tang Ziren
Lead sponsor
Capital Medical University
Sponsor institution